Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Debt / NOTE 0.750% 8/1
-
Number of holders
-
12
-
Total 13F principal, excl. options
-
181,116,000
-
Principal change
-
-48,565,000
-
Total reported value, excl. options
-
$498,208,000
-
Value change
-
-$114,297,457
-
Number of buys
-
3
-
Number of sells
-
-11
-
Price
-
$2.75
Significant Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q2 2018
18 filings reported holding 53220KAD0 - LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 as of Q2 2018.
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 8/1 has 12 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $181,116,000 of principal
.
Largest 10 bondholders include CITADEL ADVISORS LLC ($69,000,000 of principal), Polygon Management Ltd. ($29,500,000 of principal), ANGELO GORDON & CO., L.P. ($22,500,000 of principal), CALAMOS ADVISORS LLC ($17,500,000 of principal), WOLVERINE ASSET MANAGEMENT LLC ($16,298,000 of principal), SUSQUEHANNA INTERNATIONAL GROUP, LLP ($15,472,000 of principal), LORD, ABBETT & CO. LLC ($4,059,000 of principal), Periscope Capital Inc. ($4,000,000 of principal), WELLS FARGO & COMPANY/MN ($1,201,000 of principal), and JPMORGAN CHASE & CO ($1,036,000 of principal).
This table shows the top 12 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.